Alerts will be sent to your verified email
Verify Email
ERIS
|
Eris Lifesciences
|
Natco Pharma
|
Alembic Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
6.1 % | 31.2 % | n/a |
|
R&D as a % of Total Sales
|
0.0 | 9.1 % | 9.0 % |
|
Financials
|
|||
|
5 yr Average ROE
|
17.74 % | 15.58 % | 12.89 % |
|
5yr average Equity Multiplier
|
1.76 | 1.17 | 1.39 |
|
5yr Average Asset Turnover Ratio
|
0.51 | 0.48 | 0.86 |
|
5yr Avg Net Profit Margin
|
22.76 % | 26.79 % | 11.15 % |
|
Price to Book
|
6.01 | 1.84 | 2.82 |
|
P/E
|
43.06 | 10.25 | 23.84 |
|
5yr Avg Cash Conversion Cycle
|
-54.68 Days | 4.27 Days | 9.46 Days |
|
Inventory Days
|
27.48 Days | 91.91 Days | 99.1 Days |
|
Days Receivable
|
54.07 Days | 93.3 Days | 66.32 Days |
|
Days Payable
|
148.48 Days | 134.54 Days | 164.9 Days |
|
5yr Average Interest Coverage Ratio
|
66.44 | 60.49 | 30.59 |
|
5yr Avg ROCE
|
18.34 % | 19.09 % | 15.26 % |
|
5yr Avg Operating Profit Margin
|
34.43 % | 34.0 % | 17.29 % |
|
5 yr average Debt to Equity
|
0.46 | 0.06 | 0.14 |
|
5yr CAGR Net Profit
|
-0.19 % | 33.73 % | -12.64 % |
|
5yr Average Return on Assets
|
12.4 % | 13.46 % | 9.32 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.85 % | 49.48 % | 69.74 % |
|
Share Pledged by Promoters
|
16.92 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
2.15 % | 0.66 % | 0.13 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
8.62 % | -6.58 % | 2.35 % |
|
Eris Lifesciences
|
Natco Pharma
|
Alembic Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Entity Wise Breakup
|
Entity Wise Breakup
|
-
|
-
|
|
EBITDA - Entity Wise
|
EBITDA - Entity Wise
|
-
|
-
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|